FACIT

Esphera SynBio is a biotechnology company specializing in synthetic biology for disease treatment and prevention. It develops innovative cancer and immunoregulatory therapies using a proprietary platform that produces functionalized vesicles, either in vitro or in vivo, via transgene technology. Beyond oncology, the platform also shows promise in broader immunomodulation applications, such as enhancing mRNA vaccine efficacy for infectious diseases.

Hyivy Health specializes in innovative pelvic rehabilitation solutions. Its flagship product is an intelligent device designed for women experiencing pelvic health complications, offering quantifiable data tracking and three different therapies to enhance recovery and comfort.

Radiant Biotherapeutics is a pioneering company developing a modular platform for creating multi-valent and multi-specific antibodies. This innovative approach aims to deliver transformative therapies for challenging diseases like cancer, autoimmune disorders, and infections by harnessing the power of avidity and multi-specificity.

HDAX Therapeutics is a biotechnology company focused on developing small molecule therapeutics for cardiovascular and neurological diseases, with an emphasis on HDAC6-driven pathologies such as neuropathies and cardiometabolic disorders. The company is building a precision therapeutics platform based on a two-site binding mechanism to selectively inhibit HDAC6, aiming to deliver safe, efficacious, and long-lasting treatments that enable researchers to pursue novel therapies with improved accuracy and therapeutic potential.

Tenomix develops novel technologies to improve pathology workflow and colorectal cancer staging. The company’s robotic scanning device guides pathology staff in efficient and reliable lymph node collection from surgically removed colon cancer tissues, enabling accurate identification of cancer spread and supporting optimized cancer care while reducing healthcare costs.

Radiant Biotherapeutics is a pioneering company developing a modular platform for creating multi-valent and multi-specific antibodies. This innovative approach aims to deliver transformative therapies for challenging diseases like cancer, autoimmune disorders, and infections by harnessing the power of avidity and multi-specificity.

CTRL Therapeutics is a biotechnology company based in Toronto, Canada. It specializes in the research and development of cell therapies for treating cancerous tumors.

HDAX Therapeutics is a biotechnology company focused on developing small molecule therapeutics for cardiovascular and neurological diseases, with an emphasis on HDAC6-driven pathologies such as neuropathies and cardiometabolic disorders. The company is building a precision therapeutics platform based on a two-site binding mechanism to selectively inhibit HDAC6, aiming to deliver safe, efficacious, and long-lasting treatments that enable researchers to pursue novel therapies with improved accuracy and therapeutic potential.

QurCan Therapeutics develops nanotechnology-based drug delivery platforms for precision medicine in solid-tumor cancer therapy. Their platform efficiently delivers drugs, antibodies, and RNA to hard-to-reach tumors, including the brain, enhancing therapeutic outcomes.

Replica Analytics Ltd. is a Canadian company based in Ottawa that specializes in developing modeling software to create synthetic data derived from real clinical datasets. Founded in 2019, the company employs advanced machine learning technologies to generate privacy-protective synthetic data that retains the statistical properties of the original data. This platform not only facilitates the creation of high-utility synthetic datasets but also provides documentation regarding the utility characteristics of the data. By doing so, Replica Analytics enables businesses to access valuable data while adhering to global regulatory requirements for privacy protection and data analysis.

Bridge7 is a Canadian company founded in 2017 that specializes in developing AI-powered consultation software aimed at improving cancer care delivery. The software employs advanced machine learning algorithms to analyze data from thousands of patients, providing clinical teams with decision-making metrics to enhance the quality of care. This innovative approach enables healthcare providers to gain valuable insights and consultations regarding cancer treatment options before patients initiate their treatment courses, ultimately leading to increased clinical efficiency and improved quality in cancer care delivery. Headquartered in Ontario, Bridge7 is committed to ensuring that patients receive the most effective and timely care from specialized cancer treatment centers.

Founded in 2017, Xpan Inc. specializes in developing innovative surgical access instruments for minimally invasive surgeries (MIS). The company's flagship product is a universal trocar system designed to improve medical procedures by reducing incision sizes and enhancing surgical efficiency.

QurCan Therapeutics develops nanotechnology-based drug delivery platforms for precision medicine in solid-tumor cancer therapy. Their platform efficiently delivers drugs, antibodies, and RNA to hard-to-reach tumors, including the brain, enhancing therapeutic outcomes.

Cellular Analytics Inc. is a biotechnology company based in Toronto, Canada, focused on advancing cancer diagnostics through its proprietary microfluidic platform, CytoFind. This innovative technology allows for the detection and molecular characterization of rare circulating tumor cells at a single-cell level. By utilizing significantly lower sample volumes and reducing costs, CytoFind facilitates the development of liquid biopsy tests aimed at predicting patient responses to targeted therapies in immuno-oncology. The company's mission centers on enhancing the precision and efficacy of cancer treatment through advanced diagnostic solutions.

QurCan Therapeutics develops nanotechnology-based drug delivery platforms for precision medicine in solid-tumor cancer therapy. Their platform efficiently delivers drugs, antibodies, and RNA to hard-to-reach tumors, including the brain, enhancing therapeutic outcomes.

DNAstack develops a cloud-based platform for genomics data management, analysis, search, and secure sharing. It enables researchers, clinical labs, and pharmaceutical companies to efficiently accumulate and share genomic datasets while providing tools to estimate associated cloud costs.

Talon Pharmaceuticals focuses on discovering, developing, and commercializing medicines using its Multiphore drug design platform. The company specializes in treating central nervous system disorders and challenging bacterial infections.

Polumiros Inc. is a biomaterials company based in Toronto, Canada, founded in 2016. It focuses on the development of biocompatible amino acid-derived polymers that serve various medical applications, including coatings for medical devices, tissue regeneration scaffolds, and drug carriers. The company's primary innovation is its immunomodulatory polymer technology, which effectively manages inflammation and promotes healing, thereby improving patients' health and overall quality of life. One of its notable products is ReFilx, a regenerative filler matrix designed for breast cancer patients, providing an effective and minimally invasive solution for restoring breast tissue defects following lumpectomy. Polumiros aims to reduce implant-associated pain and fibrosis while enhancing bio-integration in medical procedures.

16 Bit Inc. is a Toronto-based company that develops medical image analysis systems, focusing on artificial intelligence software designed to enhance diagnostic capabilities for healthcare professionals. The company is working on a triaging algorithm specifically for breast cancer screening, as well as systems for neurological emergency detection and pediatric bone age assessment. By creating trusted AI software as a medical device, 16 Bit aims to improve the quality, efficiency, and accessibility of healthcare, ultimately assisting physicians and radiologists in interpreting medical images more effectively.

Dalriada Therapeutics Inc. is a Canadian biotechnology company, incorporated in 2016 and headquartered in Mississauga. The company specializes in the development of novel small molecule inhibitors that target various medical conditions, including oncology, pain modulation, and neurodegenerative or neuroinflammatory disorders. Dalriada employs a TURN-KEY model that aligns research and development efforts with business and intellectual property strategies, thereby supporting global innovators in the pharmaceutical sector.

DNAstack develops a cloud-based platform for genomics data management, analysis, search, and secure sharing. It enables researchers, clinical labs, and pharmaceutical companies to efficiently accumulate and share genomic datasets while providing tools to estimate associated cloud costs.

Developer of an organ-targeted Positron Emission Tomography (PET) imaging system designed for high-definition and low-dose applications in oncology, neurology, and cardiology. The company's technology offers ten times the efficiency in detecting radiotracers compared to traditional PET systems, with broad FDA clearance in the U.S.

Propellon Therapeutics is developing and commercializing novel cancer therapies targeting the WDR5 protein, essential for assembly of methyltransferase complexes and proper histone modification. The overexpression of WDR5 and resulting deregulation of epigenetic mechanisms are implicated in various cancers and correlated with poor patient survival. Established by FACIT, Propellon’s WDR5 inhibitor platform arises from discoveries, research and innovations originating from OICR.

KA Imaging designs and manufactures advanced X-ray detectors for medical and industrial applications. Its products include static detectors for pipe inspection, dual-energy detectors for baggage screening, dynamic detectors for engine inspection, and mammography detectors. The company's flagship product, Reveal, is a portable dual-energy subtraction X-ray detector cleared by the FDA, offering improved disease detection capabilities. Founded in 2015, KA Imaging is headquartered in Waterloo, Canada.

Turnstone Biologics is a clinical-stage biotechnology company focused on developing viral immunotherapies to improve cancer survival. Its lead candidate, RIVAL-01, combines three immunomodulators to stimulate immune activity and reprogram the tumor microenvironment.

CapNostics is a medical technology company focused on the development of innovative screening devices for the early detection of Barrett’s Esophagus and other upper gastrointestinal diseases. The company has created a non-endoscopic swallowable device that utilizes a medical-grade foam ball, which is compressed into a capsule. This capsule can be swallowed and deployed orally, allowing for the collection of cellular specimens without the need for invasive procedures. The device has received FDA clearance and is designed to facilitate the diagnosis of conditions such as Barrett’s Esophagus, cancer, and H. pylori infections. CapNostics is positioned to leverage advancements in genome sequencing to enhance diagnostic accuracy and aims to make its tests widely available for outpatient screening.

Turnstone Biologics is a clinical-stage biotechnology company focused on developing viral immunotherapies to improve cancer survival. Its lead candidate, RIVAL-01, combines three immunomodulators to stimulate immune activity and reprogram the tumor microenvironment.

Privacy Analytics Inc. is a Canadian company specializing in data anonymization software solutions targeted primarily at healthcare organizations, insurance and medical claims providers, and medical device manufacturers. Founded in 2007 and based in Ottawa, the firm focuses on safeguarding sensitive data while enabling its use for secondary purposes such as research, public health, and marketing. Privacy Analytics offers a range of products, including PARAT, an integrated software for de-identifying both structured and unstructured personal data, and a text anonymization solution. Additionally, the company provides an online risk assessment tool designed to assist privacy officers in managing data sharing agreements and evaluating re-identification risks. Through these offerings, Privacy Analytics helps organizations comply with privacy regulations and effectively manage the risks associated with disclosing health data. As of May 2016, Privacy Analytics operates as a subsidiary of IQVIA Holdings Inc.

Triphase Accelerator is a privately held drug development accelerator focused on advancing novel therapeutics, particularly in the field of oncology. The company specializes in acquiring and developing clinically enabled oncology assets that possess high-value potential through a shared risk model, progressing them to proof of concept before out-licensing or selling the products. Triphase aims to expedite the development process, allowing for faster and more cost-effective progression compared to traditional pharmaceutical and biotech methods, ultimately benefiting cancer patients with improved and affordable treatments. The management team at Triphase brings extensive experience in drug development, and the company has established strategic partnerships, notably with Celgene Corporation, to facilitate the rapid advancement of promising cancer therapeutics. Additionally, Triphase collaborates with the Ontario Institute of Cancer Research, MaRS Innovation, and other oncology partners to generate proof-of-concept data that serves the interests of investors, regulators, and healthcare providers.